Newsletter | January 9, 2026

01.09.26 -- Trading Places: 2025 Intensified CDMOs Recruiting Sponsor Talent

SPONSOR

This event offers short, interactive digital presentations from leading CDMOs showcasing their capabilities, facilities, and available capacity for biopharma development and fill-finish manufacturing. Attendees can explore sterile filling, lyophilization, and packaging technologies, and ask questions live. Open to pharma and biotech professionals, industry consultants, investment firms, and CDMO sponsors seeking manufacturing solutions. Click here to learn more.

INDUSTRY INSIGHTS

Class 3 Atropisomers: Capture Therapeutic Selectivity In Oncology

Atropisomers are key to modern small molecule drug development. Learn how advanced manufacturing strategies enable the isolation and scalable production of the most effective single isomer.

Advancements In Tablet Compression Tooling: What Manufacturers Need To Know

Discover how continuous manufacturing, AI-driven digital twins, and advanced tooling materials are transforming tablet compression to boost quality and cut operational costs in pharmaceutical production.

Gaining A Competitive Edge Through Regulatory Compliance Confidence

Achieving regulatory compliance confidence is paramount for safety and competitive advantage. Adherence to standards and risk mitigation are essential to avoid delays and detrimental outcomes.

FEATURED EDITORIAL

Trading Places: 2025 Intensified CDMOs Recruiting Sponsor Talent

CDMOs have valid reasons for it. Professionals on both sides say external development and manufacturing organizations want to be viewed in a better light by sponsors. Recruiting experienced sponsor-side professionals is one step to accomplishing that goal. Not exactly new, but intensified in 2025. And expect more in 2026.

The Module Type Package Wants All Your Equipment To Start Talking

A forthcoming ISPE guide uses case studies to aid in the design of plug-and-play process skids with implications for every step in the manufacturing process continuum.

INDUSTRY INSIGHTS CONTINUED

TPDs: Developing The Next Generation Of Oral Therapeutics

Targeted Protein Degraders are a revolutionary drug class with challenges in bioavailability and formulation complexity. Strategic CDMO partnerships are key to successful, scalable development.

Insights And Effective Strategies For A Successful Technology Transfer

See key strategies for seamless pharmaceutical technology transfers that accelerate time to market, ensure product quality, and meet regulatory standards across the drug lifecycle.

SPONSOR

SOLUTIONS

Fast-Track Your Antibody Drug Conjugate

Accelerate the development of ADCs with capabilities spanning clinical to commercial production, including OEB 5 handling, state-of-the-art fill/finish, and future expanded conjugation services.

HERMA Connected Solutions For Pharmaceutical Labeling

Digital services on a scale that is unique in the industry, including visual support with augmented reality, remote diagnosis via QR code, and visual spare parts search.

Validation And Quality Management Software Platform

Streamline validation and quality management with a ready-to-use, web-based platform featuring pre-designed process and templates, which eliminates start-up delays and ongoing maintenance.

OUTSOURCED PHARMA CAPABILITIES UPDATE

Find Your New CDMO At Outsourced Pharma Capabilities Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: